NCT07478809Recruiting
A Retrospective Real-World Study Based on RATIONALE-307
Long-Term Efficacy and Safety Analysis of First-Line Tislelizumab in Patients With Advanced Squamous NSCLC: a Retrospective Real-World Study Based on RATIONALE-307
Source: ClinicalTrials.gov · Last updated 27 Mar 2026
Brief summary (registry, in English)
The study aims to retrospectively collect long-term survival data from patients who received first-line tislelizumab combined with chemotherapy in the RATIONALE-307 trial, in order to enrich the evidence on long-term benefits in advanced squamous NSCLC patients from immunotherapy and to identify patients deriving greater clinical advantage.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 109 (estimated)
- First submitted
- 5 Mar 2026
- Start date
- 28 Feb 2026
- Primary completion date
- 31 Dec 2026
- Lead sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- Diseases
- Lung cancer, Childhood cancers
- NCT number
- NCT07478809
What you commit to
- Study type: Observational
- Planned participants: 109
- From 28 Feb 2026 to the primary completion date, 31 Dec 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other
- Patients who had a documented death before study completion in the RATIONALE-307 trial
Who the study is looking for
- Patients with squamous NSCLC who participated in the RATIONALE-307 trial and had no documented death before study completion
Sex: All
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College Coordinator of this site? Confirm its status | Beijing | China | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.